Hydroxychloroquine in Giant Cell Arteritis
Launched by UNIVERSITY HOSPITAL, TOULOUSE · Feb 1, 2007
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • giant celle arteritis with at least 3 ACR criteria including a disgnostic temporal artery biopsy
- • corticosteroid treatment since less than 1 month
- • age less than 85 years
- • signed informed consent
- Exclusion Criteria:
- • amaurosis fugax, loss of vision, acute lumb ischemia, angina pectoris or myocardium infarctus, mesenteric ischemia or other vascular complications related to GCA
- • low life expectancy (\<2 years)
- • corticosteroid treatment since more than 30 days whatever the dosage
- • primary corticosteroid resistance defined by persistant symptoms despite prednisone for more than 15 days
- • previous psychiatric troubles induced corticosteroids
- • hydroxychloroquine contra-indicated
About University Hospital, Toulouse
The University Hospital of Toulouse is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge scientific inquiry with comprehensive clinical services. Its multidisciplinary team of healthcare professionals collaborates with renowned researchers to facilitate pioneering studies across various medical fields, aiming to enhance treatment options and improve patient outcomes. As a prominent institution in the region, the University Hospital of Toulouse is committed to fostering an environment of excellence in both education and research within the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Agen, , France
Albi, , France
Auch, , France
Avignon, , France
Besançon, , France
Beziers, , France
Caen, , France
Dijon, , France
Foix, , France
Lavaur, , France
Limoges, , France
Lisieux, , France
Lourdes, , France
Mazamet, , France
Montauban, , France
Nantes, , France
Paris, , France
Paris, , France
Paris, , France
Suresnes, , France
Toulouse, , France
Toulouse, , France
Tours, , France
Patients applied
Trial Officials
ARLET Philippe, D
Principal Investigator
CHU Toulouse, Hôpital Purpan
SAILLER Laurent, MD
Study Director
CHU Toulouse, Service de Médecine Interne, Hôpital Purpan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials